Ledger.

Company

Royal Society Te Apārangi

Coverage

Stories naming Royal Society Te Apārangi. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

2 deals

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.

Brandon Capital portfolio Thu 8 Jul 2021 Amaroq TherapeuticsBooster Financial ServicesMana CommunicationsMedical Research Commercialisation Fund (MRCF)Royal Society Te ApārangiWellington UniVenturesBrandon CapitalCallaghan InnovationCure Kids VenturesNZ Innovation BoosterOtago Innovation LtdUniversity of OtagoCaleb Hulme-MoirDavid ChristensenDuncan MackintoshDr Sarah Diermeier
Unnamed stage NZ$14m

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

University of Otago cancer RNA spinout Amaroq Therapeutics has raised NZ$14 million led by Brandon Capital with Otago Innovation, NZ Innovation Booster and Cure Kids Ventures to advance its lncRNA-targeting cancer therapies.

Brandon BioCatalyst portfolio Thu 8 Jul 2021 Amaroq TherapeuticsMana CommunicationsMedical Research Commercialisation Fund (MRCF)Royal Society Te ApārangiBrandon CapitalCure Kids VenturesNZ Innovation BoosterOtago Innovation LtdCaleb Hulme-MoirDavid ChristensenDuncan MackintoshDr Sarah Diermeier

Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Something wrong? Tell us